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Background: E26 transformation-specific sequence-1 (ETS1) transcription factor plays 
important roles in both carcinogenesis and the progression of a wide range of malignancies. 
Aberrant ETS1 expression correlates with aggressive tumor behavior and a poorer prognosis 
in patients with various malignancies. The aim of the current study was to evaluate the   efficacy 
of a drug delivery system utilizing gambogic acid-loaded magnetic Fe3O4 nanoparticles 
(GA-MNP-Fe3O4) on the suppression of ETS1-mediated cell proliferation and migration in 
Panc-1 pancreatic cancer cells.
Methods: The effects caused by GA-MNP-Fe3O4 on the proliferation of Panc-1 pancreatic 
cancer cells were evaluated using a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay while inhibition of tumor cell migration was investigated in a scratch assay. 
The expressions of ETS1, cyclin D1, urokinase-type plasminogen activator (u-PA), and VEGF 
(vascular endothelial growth factor) were examined by Western blot to elucidate the possible 
mechanisms involved.
Results: In Panc-1 pancreatic cancer cells, we observed that application of GA-MNP-Fe3O4 
was able to suppress cancer cell proliferation and prevent cells from migrating effectively. After 
treatment, Panc-1 pancreatic cancer cells showed significantly decreased expression of ETS1, 
as well as its downstream target genes for cyclin D1, u-PA, and VEGF.
Conclusion: Our novel finding reaffirmed the significance of ETS1 in the treatment of pancreatic 
cancer, and application of GA-MNP-Fe3O4 nanoparticles targeting ETS1 should be considered 
as a promising contribution for better pancreatic cancer care.
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Introduction
Pancreatic cancer is characterized by late detection, a poor prognosis, and aggressive 
metastasis.1 Median survival for patients after initial diagnosis is as short as 6 months.2 
Even in cases where the cancer is diagnosed at an early resectable stage, the 5-year 
survival is still only 22%.3 Due to pancreatic cancer being one of the most malignant 
types of cancer to treat, a better understanding of the molecular mechanism involved 
in pancreatic cancer and subsequent identification of a specific molecular target are 
necessary to develop novel and more effective therapeutics.
E26 transformation-specific sequence-1 (ETS1) is a proto-oncoprotein belonging 
to the ETS protein family of transcription factors. These transcription factors contain a 
conserved winged helix-turn-helix DNA binding domain and regulate gene   expression 
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by binding to so-called ETS-binding sequences found in 
the promoter/enhancer regions of their target genes.4 ETS1 
plays a role in the regulation of physiologic processes such 
as cell proliferation and differentiation, and there is much 
evidence suggesting important roles for ETS1 in carcino-
genesis and progression of a wide range of malignancies, 
including pancreatic cancer.5–9 Transcriptional silencing 
of ETS1 could suppress angiogenesis of pancreatic cancer 
efficiently.10   Correlation between ETS1 overexpression and 
aggressive tumor behavior suggests that ETS1 may be an 
attractive molecular target for cancer therapy.
Gambogic acid (GA), the natural compound extracted 
from gamboges, has recently been established as a potent 
anticancer agent that can inhibit the growth of a wide 
variety of tumor cells, including hepatocellular carcinoma, 
pulmonary carcinoma, gastric cancer, breast cancer, and 
pancreatic cancer cells.11–15 However, the mechanism by 
which GA exerts its anticancer effect, particularly along 
with its target proteins, has not been clarified. Whether the 
GA-induced anticancer effect is mediated by ETS1 remains 
to be addressed. In addition, the therapeutic effect of GA is 
limited due to its poor water solubility.16 Therefore, efforts 
should be made to develop new drug delivery techniques to 
increase water solubility which could advance the biodis-
tribution of GA, enhance its deposition in tumor sites, and 
improve its therapeutic efficacy.
Various types of nanosized drug carriers, such as metal 
nanomaterials, liposomes, polymeric micelles, and dendrim-
ers, have been investigated in cancer therapy in order to mini-
mize the side effects of anticancer drugs, increase the water 
solubility of drugs, and enhance antitumoral drug efficacy.17,18 
Among them, magnetic Fe3O4 nanoparticles (MNP-Fe3O4), 
a biocompatible and superparamagnetic nanomaterial with 
satisfactory chemical stability and low toxicity, is widely 
used for targeted drug carriers with target-orientation and 
sustained-release properties.19–23
The aim of this study was to gain an insight into the 
involvement of ETS1 transcription factor in GA-loaded 
MNP-Fe3O4-induced suppression of Panc-1 pancreatic 
cancer cell proliferation and migration. To the best of our 
knowledge, no study has been carried out using GA as an 
inhibitor of the ETS1 transcription factor in pancreatic cancer 
treatment thus far. Here, for the first time, we investigate the 
probability and properties of GA-loaded MNP-Fe3O4 in the 
inhibition of Panc-1 pancreatic cancer cell proliferation and 
migration through inactivating transcription factor ETS1. GA 
was loaded onto MNP-Fe3O4 (GA-MNP-Fe3O4) as a drug 
delivery system. We then identified the viability/proliferation 
effects of GA-MNP-Fe3O4 on Panc-1 pancreatic cancer cells 
and investigated inhibition of cell migration. We further 
measured the expression of ETS1, cyclin D1,   urokinase-type 
plasminogen activator (u-PA), and vascular endothelial 
growth factor (VEGF) to study the mechanisms possibly 
involved.
Materials and methods
Main chemicals and apparatus
GA (Kanion Pharmaceutical Co, Ltd, Jiangsu, China) was 
dissolved in dimethylsulfoxide (Sigma Aldrich, St Louis, 
MO), stored at −20°C, and then diluted as needed in RPMI 
(Roswell Park Memorial Institute) 1640 medium (Gibco/BRL, 
Carlsbad, CA). Iron (III) chloride hexahydrate (FeCl3 ⋅ 6H2O) 
and iron (II) chloride tetrahydrate (FeCl2 ⋅ 4H2O) were obtained 
from Sinopharm Chemical Reagent Co, Ltd, (Shanghai, 
China). Ammonium hydroxide was purchased from Shanghai 
Lingfeng Chemical Reagent Co, Ltd, (Shanghai, China). 
Monoclonal antibodies, including ETS1, cyclin D1, u-PA, 
and VEGF, were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA). The horseradish peroxidase-conjugated 
IgG antibody was obtained from Nanjing KeyGen Biotech 
Inc, (Nanjing, China). 3-(4, 5-Dimethylthiazol-2-yl)-2, 
5-diphenyltetrazolium bromide (MTT) was obtained from 
Sigma and stored in the dark. All other reagents were of 
analytical grade. The transmission electron microscopic 
images were obtained using a JEM-2100 transmission electron 
microscope. The microscopic images were taken using an 
Olympus IX51 inverted microscope. The optical density (OD) 
at 492 nm was recorded by a multiwell spectrophotometer 
reader (Thermo Labsystems, Vantta, Finland).
Synthesis of MNP-Fe3O4
Magnetic Fe3O4 nanoparticles were prepared by coprecipi-
tation of Fe (III) and Fe (II) with ammonium hydroxide in 
a nitrogen environment. In a typical synthetic experiment, 
FeCl3 ⋅ 6H2O 2.61 g and FeCl2 ⋅ 4H2O 1.04 g were dissolved 
in 100 mL of deionized water and heated to 80°C, followed 
by slow addition of 10 mL of ammonium hydroxide with 
vigorous stirring for 20 minutes. The products were cooled to 
room temperature and extracted using a magnet. Finally, after 
being washed with ethanol and deionized water, the products 
were lyophilized and stored at room temperature.
Preparation of GA-loaded MNP-Fe3O4
GA-MNP-Fe3O4 was prepared as previously described.15,24 
In brief, MNP-Fe3O4 were well distributed in RPMI-
1640 medium with 10% heated inactivated fetal bovine serum 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
782
Wang et alInternational Journal of Nanomedicine 2012:7
using ultrasound treatment in order to obtain an MNP-Fe3O4 
colloidal suspension. GA at different concentrations was 
conjugated with the above MNP-Fe3O4 colloidal suspension 
by mechanical absorption polymerization at 4°C for 48 hours 
to achieve the formation of GA-MNP-Fe3O4 which acted as 
a drug delivery system.
Cell culture
Panc-1 pancreatic cancer cells, obtained from the Shanghai 
Institute of Cell Biology, Chinese Academy of Sciences, 
were cultured in RPMI-1640 supplemented with 10% heat-
inactivated fetal bovine serum, 100 U/mL penicillin, and 
100 µg/mL streptomycin at 37.0°C in humidified air with 
5% CO2. The cells were in log phase prior to the following 
experiments.
Cell viability/proliferation assay
The antiproliferation effects of MNP-Fe3O4, GA, and 
GA-MNP-Fe3O4 were studied with MTT assays using 
Panc-1 pancreatic cancer cells. Cells at 1 × 105/mL were 
seeded into 96-well plates and incubated for 24 hours. 
The growth medium was then replaced with 200 µL of 
prepared medium containing either GA alone or GA-MNP-
Fe3O4, in which the GA concentration was 0, 0.25, 0.5, 1, 
and 2 µmol/L. The cells were also treated by MNP-Fe3O4 
alone for evaluation of its cytotoxicity. Cells without any 
treatment were used as the control group. The cells were 
further incubated for 48 hours, and their relative viability 
was assessed using MTT assays. In brief, MTT solutions 
were added after the treatments and incubated for a fur-
ther 4 hours. Dimethylsulfoxide was added to solubilize 
the formazan crystal, and an optical density of 492 was 
recorded. The cell viability fraction (%) was calculated 
as follows: 
  OD492 nm in test cells/OD492 nm in control cells × 100%
Scratch assay
A cell migration assay was carried out by scratch assay. 
Initially, cells were plated in 6-well plates and allowed 
to form a confluent monolayer. Then the cell-surface was 
scratched using pipette tips and washed with phosphate 
buffer solution. After that, the cells were treated according 
to the above methods, allowed to fill the scratched area, and 
monitored over the course of 48 hours. Images were taken 
using an Olympus IX51 inverted microscope. Cell motility 
was quantified by measuring the distance between the migrat-
ing cell boundaries.
Western blot analysis
After the different treatments, the expressions of ETS1, cyclin 
D1, u-PA, and VEGF were detected by Western blot. Briefly, 
total protein was isolated and subjected to sodium dodecyl 
sulfate polyacrylamide gel electrophoresis, and transferred 
to a polyvinylidene fluoride membrane. After being blocked, 
the membrane was incubated with primary monoclonal 
antibodies for either anti-ETS1, cyclin D1, u-PA, VEGF, or 
anti-β-actin overnight at 4°C, and subsequently incubated 
with horseradish peroxidase-conjugated IgG antibody as 
the secondary antibody for one hour at room temperature. 
The protein bands were detected using an enhanced chemi-
luminescence detection system (Amersham, UK). After 
normalization by the corresponding expression of β-actin, 
protein expression of ETS1, cyclin D1, u-PA, and VEGF 
was determined by densitometry scans.
Statistical analysis
All the data are presented as the mean ± standard deviation. 
The F-test was used for significance testing, and P , 0.05 
was considered to be statistically significant. All tests were 
performed using the Statistical Package for Social Science 
(version 13.0; SPSS Inc, Chicago, IL).
Results and discussion
Characterization of MNP-Fe3O4
A representative transmission electron microscopic image of 
the synthesized MNP-Fe3O4 is shown in Figure 1. From the 
transmission electron microscopic image, the nanoparticles 
had a spherical shape with a diameter of about 20 nm. The 
particles had suitable dimensions to escape rapid renal excre-
tion, as well as to avoid components of the reticular endothe-
lial system, thus facilitating potentially passive targeting 
Figure 1 Transmission electron microscope image of magnetic Fe3O4 nanoparticles.
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of drugs to tumor tissue via the enhanced permeation and 
retention effect and active targeting with target orientation 
of the magnetic field, thereby increasing drug accumulation 
in tumor cells after endocytosis.25
Drug carrier role of MNP-Fe3O4
GA (C38H44O8) has five prenyl groups and six asymmetric 
centers (Figure 2A) and is a potent anticancer agent, but 
is limited in clinical administration due to its poor water 
  solubility.16 Therefore, we sought to identify the potential 
benefit of a drug delivery system containing GA-MNP-Fe3O4 
for cancer therapy in the present study. Figure 2B illustrates 
the preparation process for the drug delivery system. As 
shown in Figure 2C, unlike GA solution, no precipitation of 
GA was noted in the colloidal suspension of the GA-MNP-
Fe3O4 drug delivery system after 2 months of storage at 4°C, 
indicating that the solubility of GA was improved and the 
drug delivery system was stable during storage.
Antiproliferative effect in vitro
Inhibition of cell viability/proliferation is one of major mecha-
nisms by which chemotherapeutic agents kill cancer cells.26 
The results of cell viability after different treatments are 
shown in Figure 3. Cytotoxicity testing of a nanomaterial is the 
first-level evaluation before its biomedical application. When 
treated with MNP-Fe3O4 20 µg/mL, about 95% of the cells 
survived (Figure 3, blue column), which is consistent with 
our previous report.15 The results suggest that the MNP-Fe3O4 
synthesized in this study lacked cytotoxicity, thus ensuring a 
wide potential range of applications in the field of biomedi-
cal science and cancer therapy. GA as a single agent could 
inhibit the viability/proliferation of cancer cells (Figure 3, 
yellow column). Compared with GA alone, the viability of 
Panc-1 cells treated by GA-MNP-Fe3O4 obviously decreased 
(Figure 3, red column). Hence GA-MNP-Fe3O4 suppressed 
cancer cell proliferation effectively. Meanwhile, our results 
also indicate that the antiproliferative effect increased with 
increasing concentrations of GA, suggesting a dose-dependent 
effect in vitro. The increased antiproliferative effect may be 
due to improved GA cellular uptake by the GA-MNP-Fe3O4 
drug delivery system, which increases the water solubility 
of GA through the endocytosis pathway and then induces 
release of GA from the MNP-Fe3O4 in cancer cells to promote 
efficient cell killing, which is a common characteristic of 
nanoparticle-based drug delivery systems.27,28
The IC50 value, ie, the concentration of a drug that inhibits 
cell growth by 50% in different treatments of GA and GA-
MNP-Fe3O4, was determined from the above dose responses. 
As shown in Figure 4, the IC50 value of free GA for the cancer 
cells was 1.29 µmol/L, and GA-MNP-Fe3O4 could alter the IC50 
value to 0.52 µmol/L. The lower IC50 of GA-MNP-Fe3O4 for 
the drug delivery system could improve the therapeutic efficacy 
without high usage of GA to inhibit cancer cell proliferation.
Inhibition of cell migration
Migration and invasion of cancer cells are key steps of tumor 
metastasis.29 The effect of GA-MNP-Fe3O4 on the motility 
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Figure  2  Chemical  structure  of  GA  (A),  schematic  representation  (B),  and 
photographic image (C) of the GA-loaded MNP-Fe3O4 drug delivery system.
Abbreviations: GA, gambogic acid; MNP-Fe3O4, magnetic Fe3O4 nanoparticles.
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Figure 3 Antiproliferative effect of GA and GA-MNP-Fe3O4 on Panc-1 pancreatic 
cancer cells.
Note: Data are expressed as the mean ± standard deviation (n = 3).
Abbreviations: GA, gambogic acid; MNP-Fe3O4, magnetic Fe3O4 nanoparticles.
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of Panc-1 pancreatic cancer cells was measured in a scratch 
assay. GA alone resulted in a decrease in cell motility 
(Figure 5C), while no effects were observed on the motility 
of MNP-Fe3O4 (Figure 5B). However, compared with GA 
alone, GA-MNP-Fe3O4 (Figure 5D) dramatically inhibited 
Panc-1 pancreatic cancer cell migration. Cell motility was 
also quantified by measuring the distance between the migrat-
ing cell boundaries (Figure 5E). These results suggest that 
GA-MNP-Fe3O4 is highly effective in preventing Panc-1 
cell migration.
Potential mechanisms of inhibition  
of tumor cell proliferation and migration
ETS1 is induced by and is required for the activation of 
several genes involved in proliferation, remodeling of the 
extracellular matrix, and angiogenesis, such as u-PA and 
VEGF, all of which carry ETS-responsive elements in their 
promoters.30 Aberrant ETS1 expression appears to be associ-
ated with the pathophysiology of some malignancies,5–9 so it 
has been suggested that pharmacological inhibition of ETS1 
transcriptional activity may prove useful as a novel antican-
cer strategy. Recent reports have suggested transcriptional 
silencing of ETS1 could efficiently suppress angiogenesis in 
pancreatic cancer.10 The results from our in vitro studies have 
demonstrated that GA-MNP-Fe3O4 resulted in synergistic 
inhibition of cell proliferation and migration in pancreatic 
cancer. To address the question whether GA-MNP-Fe3O4 
inhibited cell proliferation and migration through inactivat-
ing transcription factor ETS1, the expression of ETS1 and 
its downstream target genes in Panc-1 pancreatic cancer 
cells exposed to the different treatments were examined by 
Western blot. We focused on cyclin D1, u-PA, and VEGF, 
which mediate proliferation, migration, and angiogenesis in 
several cancers and have been reported to be direct targets 
of ETS transcription factors.4 As shown in Figure 6, when 
the Panc-1 pancreatic cancer cells were treated with GA 
alone and with GA-MNP-Fe3O4 for 48 hours, not only the 
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Figure 4 IC50 of GA and GA-MNP-Fe3O4 for Panc-1 pancreatic cancer cells.
Abbreviations: GA, gambogic acid; MNP-Fe3O4, magnetic Fe3O4 nanoparticles.
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Notes:  Concentrations  of  GA  and  MNP-Fe3O4  are  1  µmol/L  and  20  µg/mL, 
respectively.
Abbreviations: GA, gambogic acid; MNP-Fe3O4, magnetic Fe3O4 nanoparticles.
Control
β-actin
ETS1
Cyclin D1
u-PA
VEGF
ETS1
0
0.2
0.4
0.6
0.8
1
Cyclin D1 u-PA VEGF
MNP-Fe3O4 GA-MNP-Fe3O4 GA
Control
R
e
l
a
t
i
v
e
 
i
n
t
e
n
s
i
t
y
 
o
f
 
p
r
o
t
e
i
n
s
MNP-Fe3O4 GA-MNP-Fe3O4 GA
Figure  6  Expression  of  ETS1,  cyclin  D1,  u-PA,  and  VEGF  protein  in  Panc-1 
pancreatic cancer cells by Western blot after treatment with GA and/or MNP-
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ETS1,  E26  transformation-specific  sequence-1  transcriptional  factor;  u-PA, 
urokinase-type plasminogen activator; VEGF, vascular endothelial growth factor.
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level of ETS1 but also that of cyclin D1, u-PA, and VEGF 
protein was significantly downregulated compared with the 
control group. It should be noted that downregulated levels 
in the GA-MNP-Fe3O4 group were lower than those in the 
GA group (P , 0.05). However, they were not obviously 
altered when the cells were treated with MNP-Fe3O4 alone 
(P . 0.05). Cyclin D is the first cyclin expressed in the cell 
cycle after stimulation by mitogenic signals, and stimulates 
cells to enter the cell cycle and complete the G1/S phase 
  transition.31 The suppressive effect of GA-MNP-Fe3O4 on 
expression of the cell cycle-related gene, cyclin D1, revealed 
that GA-MNP-Fe3O4 might inhibit Panc-1 pancreatic 
cancer cell proliferation mainly through cell cycle arrest. 
  Overexpression of u-PA triggers a series of proteolytic 
and signaling events that promote invasion and metastasis 
in various cancers.32 Moreover, we found that GA-MNP-
Fe3O4 inhibited migration behavior through suppression of 
u-PA in Panc-1 pancreatic cancer cells. Angiogenesis plays 
a critical role in tumor progression. VEGF is an important 
proangiogenic molecule, which plays a crucial role in tumor 
angiogenesis. Inhibition of VEGF activity often results 
in inhibition of tumor growth or even tumor regression.33 
Furthermore, we showed that GA-MNP-Fe3O4 significantly 
downregulated expression of VEGF, suggesting that it may 
be a viable strategy in   antiangiogenesis and anticancer thera-
pies for pancreatic cancer. These data indicate that the effects 
could be in part attributed to downregulation of transcription 
factor ETS1. GA-MNP-Fe3O4 inhibits Panc-1 pancreatic 
cancer cell proliferation and migration by targeting cyclin 
D1, u-PA, and VEGF via inactivation of ETS1.
Based on the above studies, Figure 7 schematically illus-
trates the possible processes by which the GA-MNP-Fe3O4 
drug delivery system inhibits cancer cell proliferation and 
migration. Firstly, GA was conjugated with MNP-Fe3O4 to 
construct GA-MNP-Fe3O4, which acted as a drug delivery 
system. This drug delivery system increased the water solu-
bility of GA. After endocytosis, the Panc-1 pancreatic cancer 
cells showed significantly decreased expression of ETS1, 
as well as its downstream target genes, cyclin D1, u-PA, 
and VEGF protein, to suppress cancer cell proliferation and 
prevent cells from migrating effectively.
Conclusion
GA-MNP-Fe3O4 could inhibit proliferation and migra-
tion of Panc-1 pancreatic cancer cells. This study further 
demonstrates that the effects could be in part attributable 
to downregulation of transcription factor ETS1. Thus, its 
downstream target genes which mediate cell proliferation, 
migration, and angiogenesis, ie, cyclin D1, u-PA, and VEGF, 
were downregulated as well. All these characteristics suggest 
that GA-MNP-Fe3O4 is a promising strategy targeting ETS1 
for the treatment of pancreatic cancer.
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